Oppenheimer analyst Leland Gershell assigned a Buy rating to Soleno Therapeutics (SLNO) yesterday and set a price target of $8.00. The company’s shares closed last Tuesday at $2.01.
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -0.7% and a 37.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Currently, the analyst consensus on Soleno Therapeutics is a Moderate Buy with an average price target of $8.00.
See today’s analyst top recommended stocks >>
Based on Soleno Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.38 million. In comparison, last year the company had a GAAP net loss of $10.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
